Caseware UK (AP4) 2024.0.164 2024.0.164 2024-12-312024-12-3100falsefalseThe principal activity of the company in the year under review was that of trading and investment inbloodstock2024-01-01falsetrue 12634726 2024-01-01 2024-12-31 12634726 2023-01-01 2023-12-31 12634726 2024-12-31 12634726 2023-12-31 12634726 c:Director2 2024-01-01 2024-12-31 12634726 d:CurrentFinancialInstruments 2024-12-31 12634726 d:CurrentFinancialInstruments 2023-12-31 12634726 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 12634726 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 12634726 d:ShareCapital 2024-12-31 12634726 d:ShareCapital 2023-12-31 12634726 d:RetainedEarningsAccumulatedLosses 2024-12-31 12634726 d:RetainedEarningsAccumulatedLosses 2023-12-31 12634726 c:FRS102 2024-01-01 2024-12-31 12634726 c:Audited 2024-01-01 2024-12-31 12634726 c:FullAccounts 2024-01-01 2024-12-31 12634726 c:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 12634726 c:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 12634726 e:PoundSterling 2024-01-01 2024-12-31 iso4217:GBP xbrli:pure

Registered number: 12634726










K & W BLOODSTOCK LIMITED










FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2024

 
K & W BLOODSTOCK LIMITED
REGISTERED NUMBER: 12634726

BALANCE SHEET
AS AT 31 DECEMBER 2024

2024
2023
Note
£
£

  

Current assets
  

Stocks
  
358,132
374,900

Debtors: amounts falling due within one year
 4 
214,259
10,874

Cash at bank and in hand
 5 
732,063
909,809

  
1,304,454
1,295,583

Creditors: amounts falling due within one year
 6 
(344,422)
(335,018)

Net current assets
  
 
 
960,032
 
 
960,565

Total assets less current liabilities
  
960,032
960,565

  

Net assets
  
960,032
960,565


Capital and reserves
  

Called up share capital 
  
2
2

Profit and loss account
  
960,030
960,563

  
960,032
960,565


Page 1

 
K & W BLOODSTOCK LIMITED
REGISTERED NUMBER: 12634726
    
BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2024

The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




H M Leach
Director

Date: 24 September 2025

The notes on pages 3 to 6 form part of these financial statements.

Page 2

 
K & W BLOODSTOCK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1.


General information

K & W Bloodstock Limited is a private company, limited by shares, registered in England and Wales. 
The company's registered number and registered office address as found below:
 

Registered number
12634726




Registered address
Creswell House
Fieldway
Heath
CF14 4UH
 
The presentation currency of the financial statements is the Pound Sterling (£).

Monetary amounts in these financial statements are rounded to the nearest £. 

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies.

The following principal accounting policies have been applied:

 
2.2

Going concern

The financial statements have been prepared on a going concern basis which assumes that the company will continue in operational existence for the foreseeable future. The directors have reviewed the balance sheet and the company's likely future cashflows. At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources in place to continue in operational existence for the foreseeable future. 

Page 3

 
K & W BLOODSTOCK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.3

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


  
2.4

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. 

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.5

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.6

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.7

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 4

 
K & W BLOODSTOCK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

3.


Employees

The Company has no employees other than the directors, who did not receive any remuneration (2023 - £NIL).


4.


Debtors

2024
2023
£
£


Other debtors
214,259
10,874

214,259
10,874



5.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
732,063
909,809

732,063
909,809



6.


Creditors: Amounts falling due within one year

2024
2023
£
£

Amounts owed to group undertakings
335,018
335,018

Corporation tax
9,404
-

344,422
335,018



7.


Related party transactions

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.  

Page 5

 
K & W BLOODSTOCK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

8.


Controlling party

The directors do not consider there to be an ultimate controlling party. 

The company is a wholly owned subsidiary of Knox & Wells Holdings Limited, a company registered in England and Wales. The smallest and largest group in which the company has been consolidated is Knox & Wells Holdings Limited. Copies of the consolidated financial statements of Knox & Wells Holdings Limited can be obtained from the registered office at Creswell House, Fieldway, Heath, Cardiff, CF14 4UH. 


9.


Auditor's information

The auditor's report on the financial statements for the year ended 31 December 2024 was unqualified.

The audit report was signed on 6 October 2025 by James Dobson BSc (Hons) FCA (Senior Statutory Auditor) on behalf of MHA.

MHA is the trading name of MacIntyre Hudson LLP, a limited liability partnership in England and Wales (registered number OC312313). 

 
Page 6